Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scpharmaceuticals Inc.

2.49
+0.12005.06%
Volume:141.10K
Turnover:344.44K
Market Cap:125.21M
PE:-1.30
High:2.51
Open:2.33
Low:2.24
Close:2.37
Loading ...

scPharmaceuticals Full Year 2024 Earnings: In Line With Expectations

Simply Wall St.
·
21 Mar

scPharmaceuticals Is Maintained at Buy by Maxim Group

Dow Jones
·
20 Mar

Q4 2024 scPharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Mar

Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating

MT Newswires Live
·
20 Mar

scPharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

GuruFocus.com
·
20 Mar

scPharmaceuticals Inc : Leerink Partners Cuts Target Price to $11 From $17

THOMSON REUTERS
·
20 Mar

ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
20 Mar

scPharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
20 Mar

scPharmaceuticals Q4 2024 GAAP EPS $(0.35) Beats $(0.38) Estimate, Sales $12.20M Beat $12.08M Estimate

Benzinga
·
20 Mar

BRIEF-scPharmaceuticals Q4 Revenue USD 12.15 Million Vs. IBES Estimate USD 12.1 Million

Reuters
·
20 Mar

scPharmaceuticals Q4 Net Income USD -18.845 Million VS. Ibes Estimate USD -16.6 Million

THOMSON REUTERS
·
20 Mar

scPharmaceuticals Q4 Basic EPS USD -0.35

THOMSON REUTERS
·
20 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), Intuitive Surgical (ISRG) and Labcorp Holdings (LH)

TIPRANKS
·
07 Mar

scPharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

scPharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
07 Mar

scPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix

MT Newswires Live
·
07 Mar

scPharmaceuticals Inc - Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025

THOMSON REUTERS
·
07 Mar

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease

THOMSON REUTERS
·
07 Mar